文献速递慢性肾脏病

蔗糖氢氧化氧铁在大鼠慢性肾衰竭模型中的肾脏保护作用

Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

该研究在腺嘌呤诱导的慢性肾衰竭大鼠模型中,比较了铁基磷结合剂蔗糖氢氧化氧铁(PA21)与碳酸钙对肾功能、矿物质稳态和血管钙化的影响。结果显示PA21降低血肌酐和血磷、升高离子钙,并抑制FGF-23升高、减轻血管钙化,而碳酸钙未显示贫血改善。

要点

  • PA21降低慢性肾衰竭大鼠血肌酐和血磷,升高离子钙。
  • PA21抑制FGF-23升高并减少血管钙含量,碳酸钙无此效果。
  • PA21改善贫血,碳酸钙未观察到该作用。

核心结论

  • PA21治疗可防止血清FGF-23升高,并除了降磷作用外,对肾功能下降及相关紊乱有有益影响。

研究设计与样本

  • 大鼠慢性肾衰竭模型:0.25%腺嘌呤饮食8周诱导稳定肾衰竭。
  • 同期设溶媒对照组、PA21 2.5 g/kg/天组、PA21 5.0 g/kg/天组和碳酸钙3.0 g/kg/天组。

主要发现

  • PA21 2.5或5.0 g/kg/天组治疗8周后血肌酐和血磷显著低于溶媒组,离子钙显著高于溶媒组。
  • PA21组肾功能保护更好且贫血较轻,碳酸钙组未观察到贫血改善。
  • 两种剂量PA21均防止FGF-23大幅升高并显著降低血管钙含量,碳酸钙无此作用。
  • PA21和碳酸钙均改善CKD相关甲状旁腺性骨病。

临床怎么用

  • 在大鼠模型中,PA21除降磷外可能延缓肾功能下降并改善相关紊乱,支持进一步研究其用于未透析肾功能不全患者。

局限性

  • 证据来自大鼠慢性肾衰竭模型,不能直接外推至人类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Sucroferric oxyhydroxide (PA21) is an efficacious, well-tolerated iron-based phosphate binder and a promising alternative to existing compounds. We compared the effects of PA21 with those of a conventional phosphate binder on renal function, mineral homeostasis and vascular calcification in a chronic kidney disease-mineral and bone disorder (CKD-MBD) rat model. METHODS: To induce stable renal failure, rats were administered a 0.25% adenine diet for 8 weeks. Concomitantly, rats were treated with vehicle, 2.5 g/kg/day PA21, 5.0 g/kg/day PA21 or 3.0 g/kg/day calcium carbonate (CaCO3). Renal function and calcium/phosphorus/iron metabolism were evaluated during the study course. Renal fibrosis, inflammation, vascular calcifications and bone histomorphometry were quantified. RESULTS: Rats treated with 2.5 or 5.0 g/kg/day PA21 showed significantly lower serum creatinine and phosphorus and higher ionized calcium levels after 8 weeks of treatment compared with vehicle-treated rats. The better preserved renal function with PA21 went along with less severe anaemia, which was not observed with CaCO3. Both PA21 doses, in contrast to CaCO3, prevented a dramatic increase in fibroblast growth factor (FGF)-23 and significantly reduced the vascular calcium content while both compounds ameliorated CKD-related hyperparathyroid bone. CONCLUSIONS: PA21 treatment prevented an increase in serum FGF-23 and had, aside from its phosphate-lowering capacity, a beneficial impact on renal function decline (as assessed by the renal creatinine clearance) and related disorders. The protective effect of this iron-based phosphate binder on the kidney in rats, together with its low pill burden in humans, led us to investigate its use in patients with impaired renal function not yet on dialysis.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Neven E, Corremans R, Vervaet BA, et al. Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure. Nephrol Dial Transplant. 2020. PMID: 33022710. doi:10.1093/ndt/gfaa080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。